Clinical mid-term results after tricuspid valve replacement

Giorgio Viganò, Andrea Guidotti, Maurizio Taramasso, Andrea Giacomini, Ottavio Alfieri

Research output: Contribution to journalArticlepeer-review


Tricuspid valve replacement (TVR) is associated with high mortality and morbidity. Frequently, TVR is performed in critically ill patients with high frequency of re-intervention. We analyzed our experience in TVR focusing on predicting risk factors, mid-term survival and quality of life assessed with a Short-Form 36 Health Survey (SF-36) questionnaire. Between January 1992 and May 2007, 81 consecutive patients underwent TVR (54 re-interventions, 66.7%; 46 procedures, associated with a left-sided operation, 56.8%). There were 59 females (73%) with a mean age of 59.3±11.6 years. The most prevalent etiology was rheumatic fever (61.7%). Pulmonary hypertension was present in 64%. Mean left ventricle ejection fraction (LVEF) was 56.6% and mean right ventricle ejection fraction (RVEF) was 48.1%. All but four patients (4.9%) received a bio-prosthesis. Hospital mortality was 9.88%. The mean follow-up was 61±42 months. Survival was 68% at five years. Univariate predictors of hospital mortality were atrial fibrillation (AFib) (P-0.01), associated procedures on the left heart (P

Original languageEnglish
Pages (from-to)709-713
Number of pages5
JournalInteractive Cardiovascular and Thoracic Surgery
Issue number5
Publication statusPublished - May 2010


  • Heart failure
  • Heart valve
  • Quality of life
  • Tricuspid valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery


Dive into the research topics of 'Clinical mid-term results after tricuspid valve replacement'. Together they form a unique fingerprint.

Cite this